Jefferies Financial Group’s Cytokinetics CYTK Stock Holding History

Jefferies Financial Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,600	Closed	-$593K	–	1689
2024 Q4	$593K	Buy	+12,600	New	+$654K	﹤0.01%	1064
2024 Q3	–	Sell	-8,220	Closed	-$445K	–	1505
2024 Q2	$445K	Sell	8,220 -23,800	-74%	-$1.44M	﹤0.01%	1006
2024 Q1	$2.24M	Buy	32,020 +6,812	+27%	+$527K	0.02%	550
2023 Q4	$2.1M	Buy	+25,208	New	+$913K	0.01%	693
2023 Q3	–	Sell	-35,550	Closed	-$1.16M	–	1673
2023 Q2	$1.16M	Sell	35,550 -4,450	-11%	-$165K	0.01%	859
2023 Q1	$1.41M	Buy	+40,000	New	+$1.63M	0.01%	769

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Financial Group's CYTK Position: Q1 2025 in Review

Jefferies Financial Group sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 12,600 shares — an estimated $593K sold.

Jefferies Financial Group first reported a position in CYTK in Q1 2023 and held it in 6 quarters. The position peaked at $2.24M in Q1 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

Jefferies Financial Group reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
Jefferies Financial Group sold 12,600 Cytokinetics shares in Q1 2025, an estimated $593K.
Jefferies Financial Group first reported a position in Cytokinetics in Q1 2023 and held it in 6 quarters.
Jefferies Financial Group's Cytokinetics position peaked at $2.24M in Q1 2024.
355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Jefferies Financial Group's 13F filing for Q1 2025, filed 8 May 2025.